Accessibility Menu
Arrow-Thin-Down
S&P 500
6,896.24
-0.1%
-9.50
Arrow-Thin-Down
DJI
48,367.06
-0.2%
-94.87
Arrow-Thin-Down
NASDAQ
23,419.08
-0.2%
-55.27
Arrow-Thin-Down
Bitcoin
$88,672.00
+0.9%
+$763.90
Arrow-Thin-Down
QBTS
$26.25
+0.4%
+$0.10
Arrow-Thin-Down
HYMC
$23.48
+0.9%
+$0.22
Arrow-Thin-Down
RGC
$22.90
-2.5%
-$0.58
Arrow-Thin-Down
PRAX
$297.02
-2.5%
-$7.56
Arrow-Thin-Down
RARE
$22.78
+15.5%
+$3.06
Arrow-Thin-Down
PTON
$6.23
-0.6%
-$0.04
Arrow-Thin-Down
AMZN
$232.68
+0.3%
+$0.61
Arrow-Thin-Down
GOOG
$314.74
+0.1%
+$0.35
Arrow-Thin-Down
META
$666.28
+1.2%
+$7.59
Arrow-Thin-Down
MSFT
$487.79
+0.1%
+$0.69
Arrow-Thin-Down
NVDA
$187.73
-0.3%
-$0.49
Arrow-Thin-Down
TSLA
$454.82
-1.0%
-$4.82
Daily Stock GainersDaily Stock LosersMost Active Stocks
Bright Minds Biosciences Stock Quote

Bright Minds Biosciences (NASDAQ: DRUG)

$75.85
(-2.9%)
-2.27
Price as of December 30, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$75.85
Daily Change
(-2.9%) $2.27
Day's Range
$75.70 - $81.00
Previous Close
$75.85
Open
$78.26
Beta
1.02
Volume
3
Average Volume
161,721
Sector
Health Care
Market Cap
$591M
Market Cap / Employee
$75.85M
52wk Range
$23.18 - $97.75
Revenue
N/A
Gross Margin
N/A
Dividend Yield
N/A
EPS
-$1.24
CAPs Rating
N/A
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Bright Minds Biosciences Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
DRUG+105.78%N/AN/A+181%
S&P+16.75%+83.6%+12.92%+75%
Advertisement

Bright Minds Biosciences Company Info

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in New York, NY.

News & Analysis

Featured Article

Why Bright Minds Biosciences Stock Topped the Market on Monday

The company isn't wasting any time drafting seasoned professionals to help it develop medication for a rare genetic disorder.

Eric Volkman  |  Nov 17, 2025
Featured Article

Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month

The reason for the stock's rapid ascent is a mystery.

David Jagielski, CPA  |  Nov 13, 2024

Financial Health

General

Q3 2025YOY Change
Revenue$0.00K0.0%
Gross Profit-$12.35K11.4%
Market Cap$429.75M8128.6%
Market Cap / Employee$0.00K0.0%
Employees00.0%
Net Income-$2,966.35K-423.1%
EBITDA-$4,095.09K-625.7%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q3 2025YOY Change
Net Cash$59.52M1327.3%
Inventory00.0%

Liabilities

Q3 2025YOY Change
Long Term Debt$29.65K1.2%
Short Term Debt$60.75K3.4%

Ratios

Q3 2025YOY Change
Return On Assets-26.92%16.0%
Return On Invested Capital-84.68%2.4%

Cash Flow

Q3 2025YOY Change
Free Cash Flow-$946.29K-176.1%
Operating Free Cash Flow-$946.29K-176.1%

Valuation

MetricQ4 2024Q1 2025Q2 2025Q3 2025YoY Change
Price to Book39.766.274.7811.31865.61%
Price to Tangible Book Value39.766.274.7811.31865.61%
Enterprise Value to EBITDA-172.86-93.70-63.32-91.636557.30%
Return on Equity-3.5%-11.3%-30.0%-27.8%-39.39%
Total Debt$127.06K$115.75K$103.36K$90.40K2.66%

No results found

No podcast episodes available.

No results found

No transcripts available.

Advertisement

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services